Charles Schwab’s DiaMedica Therapeutics DMAC Stock Holding History

Charles Schwab’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$681K	Buy	96,691 +8,270	+9%	+$50.8K	﹤0.01%	3136
2026 Q1	$599K	Sell	88,421 -8,459	-9%	-$67K	﹤0.01%	3050
2025 Q4	$771K	Buy	96,880 +4,453	+5%	+$33.3K	﹤0.01%	3013
2025 Q3	$635K	Buy	92,427 +12,874	+16%	+$69.8K	﹤0.01%	3098
2025 Q2	$310K	Buy	79,553 +66,300	+500%	+$259K	﹤0.01%	3299
2025 Q1	$50.2K	Buy	13,253 +2	+0%	+$11	﹤0.01%	3399
2024 Q4	$72K	Hold	13,251	–	–	﹤0.01%	3420
2024 Q3	$55.5K	Hold	13,251	–	–	﹤0.01%	3407
2024 Q2	$39.1K	Hold	13,251	–	–	﹤0.01%	3536
2024 Q1	$36.7K	Hold	13,251	–	–	﹤0.01%	3391
2023 Q4	$37.6K	Hold	13,251	–	–	﹤0.01%	3432
2023 Q3	$34.2K	Hold	13,251	–	–	﹤0.01%	3446
2023 Q2	$57.2K	Buy	+13,251	New	+$32.2K	﹤0.01%	3404

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Charles Schwab's DMAC Position: Q2 2026 in Review

Charles Schwab increased its DiaMedica Therapeutics (DMAC) stake by 9.4% in Q2 2026, buying an estimated $50.8K and bringing the position to 96,691 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

Charles Schwab first reported a position in DMAC in Q2 2023 and has held it in 13 quarters since. The position peaked at $771K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Charles Schwab held 96,691 shares of DiaMedica Therapeutics worth $681K as of Q2 2026.
Charles Schwab bought 8,270 DiaMedica Therapeutics shares in Q2 2026, an estimated $50.8K.
DiaMedica Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3136 holding.
Charles Schwab first reported a position in DiaMedica Therapeutics in Q2 2023 and has held it in 13 quarters since.
Charles Schwab's DiaMedica Therapeutics position peaked at $771K in Q4 2025.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.